# Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

> **NCT07364474** · NA · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Melphalan through Percutaneous Hepatic Perfusion

## Key facts

- **NCT ID:** NCT07364474
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2027-12
- **Final completion:** 2028-09
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07364474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07364474, "Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07364474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*